Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Resilience and Lifera to build a biopharmaceutical plant in Saudi Arabia

by Rick Mullin
August 31, 2023 | A version of this story appeared in Volume 101, Issue 29

 

National Resilience, a biopharmaceutical development and manufacturing firm, has entered an agreement with Lifera, owned by a private investment fund, to develop biopharmaceutical production in Riyadh, Saudi Arabia. Resilience, which debuted in 2020, will undertake the design, construction, and commissioning of a plant that meets the quality standard of the US Food and Drug Administration’s current good manufacturing practices. Resilience will have a minority ownership stake in the plant, which will produce sterile injectables and other parenteral products to meet local and regional demand.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.